APO Research
Talk to an analyst

APO RESEARCH · REPORT

mRNA Vaccine Drugs Development Services

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global mRNA Vaccine Drugs Development Services Market Outlook and Growth Opportunities 2026

5 June 2026192 pages

Choose your research edition.

Industry ResearchmRNA Vaccine Drugs Development Services Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal mRNA Vaccine Drugs Development Services Industry Growth and Trends Forecast to 2032103 pages · $3,450 USDMarket StructureGlobal mRNA Vaccine Drugs Development Services Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032193 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal mRNA Vaccine Drugs Development Services Market Outlook and Growth Opportunities 2026192 pages · $4,250 USDMarket Analysis & ForecastGlobal mRNA Vaccine Drugs Development Services Market Analysis and Forecast 2026-2032231 pages · $4,950 USD

Market perspective

The global mRNA Vaccine Drugs Development Services market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for mRNA Vaccine Drugs Development Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for mRNA Vaccine Drugs Development Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for mRNA Vaccine Drugs Development Services is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the mRNA Vaccine Drugs Development Services market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the mRNA Vaccine Drugs Development Services market include ReciBioPharm, Merck, Samsung Biologics, Thermo Fisher Scientific, Lonza, Ricoh Group, Aldevron, Wuxi Biologics and Genscript Probio, among others. In 2025, the top three vendors together accounted for approximately % of global market revenue.

This report provides an overview of the global mRNA Vaccine Drugs Development Services market in terms of revenue and gross margin, analyzing global market trends using historical revenue data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of mRNA Vaccine Drugs Development Services and market revenue by major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents mRNA Vaccine Drugs Development Services revenue, market share, and industry ranking for the main companies for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

Across the 2021-2026 period, the analysis compares revenue growth and profitability profiles by company, distinguishing participants with sustained expansion from those with more cyclical performance, and relates these patterns to differences in regional exposure, product portfolios, and application focus in the global mRNA Vaccine Drugs Development Services market.

mRNA Vaccine Drugs Development Services Segment by Company

ReciBioPharm

Merck

Samsung Biologics

Thermo Fisher Scientific

Lonza

Ricoh Group

Aldevron

Wuxi Biologics

Genscript Probio

Novoprotein

Porton Advanced Solutions

Precision NanoSystems

mRNA Vaccine Drugs Development Services Segment by Type

mRNA Process Development Services

mRNA Synthesis Services

mRNA Drug Substance Purification Services

Others

mRNA Vaccine Drugs Development Services Segment by Application

Non-Replicating mRNA Vaccine Drugs

Self-Amplifying mRNA Vaccine Drugs

mRNA Vaccine Drugs Development Services Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global mRNA Vaccine Drugs Development Services status and future forecast, involving, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the mRNA Vaccine Drugs Development Services key companies, revenue, market share, and recent developments.

3. To split the mRNA Vaccine Drugs Development Services breakdown data by regions, type, companies, and application.

4. To analyze the global and key regions mRNA Vaccine Drugs Development Services market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify mRNA Vaccine Drugs Development Services significant trends, drivers, influence factors in global and regions.

6. To analyze mRNA Vaccine Drugs Development Services competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global mRNA Vaccine Drugs Development Services market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of mRNA Vaccine Drugs Development Services and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of mRNA Vaccine Drugs Development Services.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, global total market size.

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global mRNA Vaccine Drugs Development Services industry.

Chapter 3: Detailed analysis of mRNA Vaccine Drugs Development Services company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales value of mRNA Vaccine Drugs Development Services in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of key country in the world.

Chapter 7: Sales value of mRNA Vaccine Drugs Development Services in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.

Chapter 9: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. mRNA Vaccine Drugs Development Services Industry Trends Table 2. mRNA Vaccine Drugs Development Services Industry Drivers Table 3. mRNA Vaccine Drugs Development Services Industry Opportunities and Challenges Table 4. mRNA Vaccine Drugs Development Services Industry Restraints Table 5. Global mRNA Vaccine Drugs Development Services Revenue by Company (US$ Million) & (2021-2026) Table 6. Global mRNA Vaccine Drugs Development Services Revenue Share by Company (2021-2026) Table 7. Global mRNA Vaccine Drugs Development Services Company Ranking, (2024-2026) & (US$ Million) Table 8. Global mRNA Vaccine Drugs Development Services Key Company Manufacturing Base & Headquarters Table 9. Global mRNA Vaccine Drugs Development Services Company, Product Type & Application Table 10. Global mRNA Vaccine Drugs Development Services Company Establishment Date Table 11. Global Company Market Concentration Ratio (CR5 and HHI) Table 12. Global mRNA Vaccine Drugs Development Services by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 13. Mergers & Acquisitions, Expansion Table 14. Significant Companies of mRNA Process Development Services Table 15. Significant Companies of mRNA Synthesis Services Table 16. Significant Companies of mRNA Drug Substance Purification Services Table 17. Significant Companies of Others Table 18. Global mRNA Vaccine Drugs Development Services Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 19. Global mRNA Vaccine Drugs Development Services Sales Value by Type (2021-2026) & (US$ Million) Table 20. Global mRNA Vaccine Drugs Development Services Sales Value by Type (2027-2032) & (US$ Million) Table 21. Global mRNA Vaccine Drugs Development Services Sales Value Share by Type (2021-2026) Table 22. Global mRNA Vaccine Drugs Development Services Sales Value Share by Type (2027-2032) Table 23. Significant Companies of Non-Replicating mRNA Vaccine Drugs Table 24. Significant Companies of Self-Amplifying mRNA Vaccine Drugs Table 25. Global mRNA Vaccine Drugs Development Services Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global mRNA Vaccine Drugs Development Services Sales Value by Application (2021-2026) & (US$ Million) Table 27. Global mRNA Vaccine Drugs Development Services Sales Value by Application (2027-2032) & (US$ Million) Table 28. Global mRNA Vaccine Drugs Development Services Sales Value Share by Application (2021-2026) Table 29. Global mRNA Vaccine Drugs Development Services Sales Value Share by Application (2027-2032) Table 30. Global mRNA Vaccine Drugs Development Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global mRNA Vaccine Drugs Development Services Sales Value by Region (2021-2026) & (US$ Million) Table 32. Global mRNA Vaccine Drugs Development Services Sales Value Share by Region (2021-2026) Table 33. Global mRNA Vaccine Drugs Development Services Sales Value by Region (2027-2032) & (US$ Million) Table 34. Global mRNA Vaccine Drugs Development Services Sales Value Share by Region (2027-2032) Table 35. Global mRNA Vaccine Drugs Development Services Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 36. Global mRNA Vaccine Drugs Development Services Sales Value by Country (2021-2026) & (US$ Million) Table 37. Global mRNA Vaccine Drugs Development Services Sales Value Market Share by Country (2021-2026) Table 38. Global mRNA Vaccine Drugs Development Services Sales Value by Country (2027-2032) & (US$ Million) Table 39. Global mRNA Vaccine Drugs Development Services Sales Value Market Share by Country (2027-2032) Table 40. ReciBioPharm Company Information Table 41. ReciBioPharm Business Overview Table 42. ReciBioPharm mRNA Vaccine Drugs Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 43. ReciBioPharm mRNA Vaccine Drugs Development Services Product Portfolio Table 44. ReciBioPharm Recent Development Table 45. Merck Company Information Table 46. Merck Business Overview Table 47. Merck mRNA Vaccine Drugs Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 48. Merck mRNA Vaccine Drugs Development Services Product Portfolio Table 49. Merck Recent Development Table 50. Samsung Biologics Company Information Table 51. Samsung Biologics Business Overview Table 52. Samsung Biologics mRNA Vaccine Drugs Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 53. Samsung Biologics mRNA Vaccine Drugs Development Services Product Portfolio Table 54. Samsung Biologics Recent Development Table 55. Thermo Fisher Scientific Company Information Table 56. Thermo Fisher Scientific Business Overview Table 57. Thermo Fisher Scientific mRNA Vaccine Drugs Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 58. Thermo Fisher Scientific mRNA Vaccine Drugs Development Services Product Portfolio Table 59. Thermo Fisher Scientific Recent Development Table 60. Lonza Company Information Table 61. Lonza Business Overview Table 62. Lonza mRNA Vaccine Drugs Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 63. Lonza mRNA Vaccine Drugs Development Services Product Portfolio Table 64. Lonza Recent Development Table 65. Ricoh Group Company Information Table 66. Ricoh Group Business Overview Table 67. Ricoh Group mRNA Vaccine Drugs Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 68. Ricoh Group mRNA Vaccine Drugs Development Services Product Portfolio Table 69. Ricoh Group Recent Development Table 70. Aldevron Company Information Table 71. Aldevron Business Overview Table 72. Aldevron mRNA Vaccine Drugs Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 73. Aldevron mRNA Vaccine Drugs Development Services Product Portfolio Table 74. Aldevron Recent Development Table 75. Wuxi Biologics Company Information Table 76. Wuxi Biologics Business Overview Table 77. Wuxi Biologics mRNA Vaccine Drugs Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 78. Wuxi Biologics mRNA Vaccine Drugs Development Services Product Portfolio Table 79. Wuxi Biologics Recent Development Table 80. Genscript Probio Company Information Table 81. Genscript Probio Business Overview Table 82. Genscript Probio mRNA Vaccine Drugs Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 83. Genscript Probio mRNA Vaccine Drugs Development Services Product Portfolio Table 84. Genscript Probio Recent Development Table 85. Novoprotein Company Information Table 86. Novoprotein Business Overview Table 87. Novoprotein mRNA Vaccine Drugs Development Services Revenue (US$ Million) and Gross Margin (2021-2026) Table 88. Novoprotein mRNA Vaccine Drugs Development Services Product Portfolio Table 89. Novoprotein Recent Development Table 90. Porton Advanced Solutions Company Information Table 91. Porton Advanced Solutions Business Overview Table 92. Porton Advanced Solutions mRNA Vaccine Drugs Development Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 93. Porton Advanced Solutions mRNA Vaccine Drugs Development Services Product Portfolio Table 94. Porton Advanced Solutions Recent Development Table 95. Precision NanoSystems Company Information Table 96. Precision NanoSystems Business Overview Table 97. Precision NanoSystems mRNA Vaccine Drugs Development Services Sales (k units), Value (US$ Million), Price (USD/unit) and Gross Margin (2021-2026) Table 98. Precision NanoSystems mRNA Vaccine Drugs Development Services Product Portfolio Table 99. Precision NanoSystems Recent Development Table 100. Research Programs/Design for This Report Table 101. Authors List of This Report Table 102. Secondary Sources Table 103. Primary Sources List of Figures Figure 1. mRNA Vaccine Drugs Development Services Product Image Figure 2. Global mRNA Vaccine Drugs Development Services Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global mRNA Vaccine Drugs Development Services Market Size (2021-2032) & (US$ Million) Figure 4. Global mRNA Vaccine Drugs Development Services Company Revenue Ranking in 2025 (US$ Million) Figure 5. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 6. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 7. mRNA Process Development Services Image Figure 8. mRNA Synthesis Services Image Figure 9. mRNA Drug Substance Purification Services Image Figure 10. Others Image Figure 11. Global mRNA Vaccine Drugs Development Services Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 12. Global mRNA Vaccine Drugs Development Services Sales Value Share 2021 VS 2025 VS 2032 Figure 13. Global mRNA Vaccine Drugs Development Services Sales Value Share by Type (2021-2032) Figure 14. Non-Replicating mRNA Vaccine Drugs Image Figure 15. Self-Amplifying mRNA Vaccine Drugs Image Figure 16. Global mRNA Vaccine Drugs Development Services Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global mRNA Vaccine Drugs Development Services Sales Value Share 2021 VS 2025 VS 2032 Figure 18. Global mRNA Vaccine Drugs Development Services Sales Value Share by Application (2021-2032) Figure 19. Global mRNA Vaccine Drugs Development Services Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 20. Global mRNA Vaccine Drugs Development Services Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 21. North America mRNA Vaccine Drugs Development Services Sales Value (2021-2032) & (US$ Million) Figure 22. North America mRNA Vaccine Drugs Development Services Sales Value Share by Country (%), 2025 VS 2032 Figure 23. Europe mRNA Vaccine Drugs Development Services Sales Value (2021-2032) & (US$ Million) Figure 24. Europe mRNA Vaccine Drugs Development Services Sales Value Share by Country (%), 2025 VS 2032 Figure 25. Asia-Pacific mRNA Vaccine Drugs Development Services Sales Value (2021-2032) & (US$ Million) Figure 26. Asia-Pacific mRNA Vaccine Drugs Development Services Sales Value Share by Country (%), 2025 VS 2032 Figure 27. South America mRNA Vaccine Drugs Development Services Sales Value (2021-2032) & (US$ Million) Figure 28. South America mRNA Vaccine Drugs Development Services Sales Value Share by Country (%), 2025 VS 2032 Figure 29. Middle East & Africa mRNA Vaccine Drugs Development Services Sales Value (2021-2032) & (US$ Million) Figure 30. Middle East & Africa mRNA Vaccine Drugs Development Services Sales Value Share by Country (%), 2025 VS 2032 Figure 31. USA mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 32. USA mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 33. USA mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 34. Canada mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 35. Canada mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 36. Canada mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 37. Mexico mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 38. Mexico mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 39. Mexico mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 40. Germany mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. Germany mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. Germany mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. France mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. France mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. France mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. U.K. mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. U.K. mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. U.K. mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Italy mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Italy mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Italy mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. Spain mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. Spain mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. Spain mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. Russia mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. Russia mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. Russia mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Netherlands mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Netherlands mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Netherlands mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Nordic Countries mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Nordic Countries mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Nordic Countries mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. China mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. China mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. China mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Japan mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Japan mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Japan mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. South Korea mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. South Korea mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. South Korea mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. India mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. India mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. India mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Australia mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Australia mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Australia mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. Southeast Asia mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. Southeast Asia mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. Southeast Asia mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. Brazil mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. Brazil mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. Brazil mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Argentina mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Argentina mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Argentina mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Chile mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Chile mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Chile mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Colombia mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Colombia mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Colombia mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Peru mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Peru mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Peru mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Saudi Arabia mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Saudi Arabia mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Saudi Arabia mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Israel mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Israel mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Israel mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. UAE mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. UAE mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. UAE mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Turkey mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Turkey mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Turkey mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Iran mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Iran mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Iran mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. Egypt mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. Egypt mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. Egypt mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Years Considered Figure 116. Research Process Figure 117. Key Executives Interviewed

Scope & coverage.

Types
  • mRNA Process Development Services
  • mRNA Synthesis Services
  • mRNA Drug Substance Purification Services
  • Others
Applications
  • Non-Replicating mRNA Vaccine Drugs
  • Self-Amplifying mRNA Vaccine Drugs
Companies covered
  • ReciBioPharm
  • Merck
  • Samsung Biologics
  • Thermo Fisher Scientific
  • Lonza
  • Ricoh Group
  • Aldevron
  • Wuxi Biologics
  • Genscript Probio
  • Novoprotein
  • Porton Advanced Solutions
  • Precision NanoSystems

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global mRNA Vaccine Drugs Development Services Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global mRNA Vaccine Drugs Development Services Market Size (2021-2032)
  4. 1.4 Assumptions and Limitations
  5. 1.5 Study Goals and Objectives
2 mRNA Vaccine Drugs Development Services Market Dynamics
  1. 2.1 mRNA Vaccine Drugs Development Services Industry Trends
  2. 2.2 mRNA Vaccine Drugs Development Services Industry Drivers
  3. 2.3 mRNA Vaccine Drugs Development Services Industry Opportunities and Challenges
  4. 2.4 mRNA Vaccine Drugs Development Services Industry Restraints
3 mRNA Vaccine Drugs Development Services Market by Company
  1. 3.1 Global mRNA Vaccine Drugs Development Services Company Revenue Ranking in 2025
  2. 3.2 Global mRNA Vaccine Drugs Development Services Revenue by Company (2021-2026)
  3. 3.3 Global mRNA Vaccine Drugs Development Services Company Ranking (2024-2026)
  4. 3.4 Global mRNA Vaccine Drugs Development Services Company Manufacturing Base and Headquarters
  5. 3.5 Global mRNA Vaccine Drugs Development Services Company Product Type and Application
  6. 3.6 Global mRNA Vaccine Drugs Development Services Company Establishment Date
  7. 3.7 Market Competitive Analysis
  8. 3.7.1 Global mRNA Vaccine Drugs Development Services Market Concentration Ratio (CR5 and HHI)
  9. 3.7.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  10. 3.7.3 2025 mRNA Vaccine Drugs Development Services Tier 1, Tier 2, and Tier 3 Companies
  11. 3.8 Mergers and Acquisitions Expansion
4 mRNA Vaccine Drugs Development Services Market by Type
  1. 4.1 mRNA Vaccine Drugs Development Services Type Introduction
  2. 4.1.1 mRNA Process Development Services
  3. 4.1.2 mRNA Synthesis Services
  4. 4.1.3 mRNA Drug Substance Purification Services
  5. 4.1.4 Others
  6. 4.2 Global mRNA Vaccine Drugs Development Services Sales Value by Type
  7. 4.2.1 Global mRNA Vaccine Drugs Development Services Sales Value by Type (2021 VS 2025 VS 2032)
  8. 4.2.2 Global mRNA Vaccine Drugs Development Services Sales Value by Type (2021-2032)
  9. 4.2.3 Global mRNA Vaccine Drugs Development Services Sales Value Share by Type (2021-2032)
5 mRNA Vaccine Drugs Development Services Market by Application
  1. 5.1 mRNA Vaccine Drugs Development Services Application Introduction
  2. 5.1.1 Non-Replicating mRNA Vaccine Drugs
  3. 5.1.2 Self-Amplifying mRNA Vaccine Drugs
  4. 5.2 Global mRNA Vaccine Drugs Development Services Sales Value by Application
  5. 5.2.1 Global mRNA Vaccine Drugs Development Services Sales Value by Application (2021 VS 2025 VS 2032)
  6. 5.2.2 Global mRNA Vaccine Drugs Development Services Sales Value by Application (2021-2032)
  7. 5.2.3 Global mRNA Vaccine Drugs Development Services Sales Value Share by Application (2021-2032)
6 mRNA Vaccine Drugs Development Services Regional Value Analysis
  1. 6.1 Global mRNA Vaccine Drugs Development Services Sales Value by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global mRNA Vaccine Drugs Development Services Sales Value by Region (2021-2032)
  3. 6.2.1 Global mRNA Vaccine Drugs Development Services Sales Value by Region: 2021-2026
  4. 6.2.2 Global mRNA Vaccine Drugs Development Services Sales Value by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America mRNA Vaccine Drugs Development Services Sales Value (2021-2032)
  7. 6.3.2 North America mRNA Vaccine Drugs Development Services Sales Value Share by Country, 2025 VS 2032
  8. 6.4 Europe
  9. 6.4.1 Europe mRNA Vaccine Drugs Development Services Sales Value (2021-2032)
  10. 6.4.2 Europe mRNA Vaccine Drugs Development Services Sales Value Share by Country, 2025 VS 2032
  11. 6.5 Asia-Pacific
  12. 6.5.1 Asia-Pacific mRNA Vaccine Drugs Development Services Sales Value (2021-2032)
  13. 6.5.2 Asia-Pacific mRNA Vaccine Drugs Development Services Sales Value Share by Country, 2025 VS 2032
  14. 6.6 South America
  15. 6.6.1 South America mRNA Vaccine Drugs Development Services Sales Value (2021-2032)
  16. 6.6.2 South America mRNA Vaccine Drugs Development Services Sales Value Share by Country, 2025 VS 2032
  17. 6.7 Middle East & Africa
  18. 6.7.1 Middle East & Africa mRNA Vaccine Drugs Development Services Sales Value (2021-2032)
  19. 6.7.2 Middle East & Africa mRNA Vaccine Drugs Development Services Sales Value Share by Country, 2025 VS 2032
7 mRNA Vaccine Drugs Development Services Country-level Value Analysis
  1. 7.1 Global mRNA Vaccine Drugs Development Services Sales Value by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global mRNA Vaccine Drugs Development Services Sales Value by Country (2021-2032)
  3. 7.2.1 Global mRNA Vaccine Drugs Development Services Sales Value by Country (2021-2026)
  4. 7.2.2 Global mRNA Vaccine Drugs Development Services Sales Value by Country (2027-2032)
  5. 7.3 USA
  6. 7.3.1 USA mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  7. 7.3.2 USA mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  8. 7.3.3 USA mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  9. 7.4 Canada
  10. 7.4.1 Canada mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  11. 7.4.2 Canada mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  12. 7.4.3 Canada mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  13. 7.5 Mexico
  14. 7.5.1 Mexico mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  15. 7.5.2 Mexico mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  16. 7.5.3 Mexico mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  17. 7.6 Germany
  18. 7.6.1 Germany mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Germany mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Germany mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  21. 7.7 France
  22. 7.7.1 France mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  23. 7.7.2 France mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  24. 7.7.3 France mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  25. 7.8 U.K.
  26. 7.8.1 U.K. mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  27. 7.8.2 U.K. mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  28. 7.8.3 U.K. mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  29. 7.9 Italy
  30. 7.9.1 Italy mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  31. 7.9.2 Italy mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  32. 7.9.3 Italy mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  33. 7.10 Spain
  34. 7.10.1 Spain mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  35. 7.10.2 Spain mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  36. 7.10.3 Spain mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  37. 7.11 Russia
  38. 7.11.1 Russia mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  39. 7.11.2 Russia mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  40. 7.11.3 Russia mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  41. 7.12 Netherlands
  42. 7.12.1 Netherlands mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  43. 7.12.2 Netherlands mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  44. 7.12.3 Netherlands mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  45. 7.13 Nordic Countries
  46. 7.13.1 Nordic Countries mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  47. 7.13.2 Nordic Countries mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  48. 7.13.3 Nordic Countries mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  49. 7.14 China
  50. 7.14.1 China mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  51. 7.14.2 China mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  52. 7.14.3 China mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  53. 7.15 Japan
  54. 7.15.1 Japan mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  55. 7.15.2 Japan mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  56. 7.15.3 Japan mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  57. 7.16 South Korea
  58. 7.16.1 South Korea mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  59. 7.16.2 South Korea mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  60. 7.16.3 South Korea mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  61. 7.17 India
  62. 7.17.1 India mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  63. 7.17.2 India mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  64. 7.17.3 India mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  65. 7.18 Australia
  66. 7.18.1 Australia mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  67. 7.18.2 Australia mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  68. 7.18.3 Australia mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  69. 7.19 Southeast Asia
  70. 7.19.1 Southeast Asia mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  71. 7.19.2 Southeast Asia mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  72. 7.19.3 Southeast Asia mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  73. 7.20 Brazil
  74. 7.20.1 Brazil mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  75. 7.20.2 Brazil mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  76. 7.20.3 Brazil mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  77. 7.21 Argentina
  78. 7.21.1 Argentina mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  79. 7.21.2 Argentina mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  80. 7.21.3 Argentina mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  81. 7.22 Chile
  82. 7.22.1 Chile mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  83. 7.22.2 Chile mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  84. 7.22.3 Chile mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  85. 7.23 Colombia
  86. 7.23.1 Colombia mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  87. 7.23.2 Colombia mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  88. 7.23.3 Colombia mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  89. 7.24 Peru
  90. 7.24.1 Peru mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  91. 7.24.2 Peru mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  92. 7.24.3 Peru mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  93. 7.25 Saudi Arabia
  94. 7.25.1 Saudi Arabia mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  95. 7.25.2 Saudi Arabia mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  96. 7.25.3 Saudi Arabia mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  97. 7.26 Israel
  98. 7.26.1 Israel mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  99. 7.26.2 Israel mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  100. 7.26.3 Israel mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  101. 7.27 UAE
  102. 7.27.1 UAE mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  103. 7.27.2 UAE mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  104. 7.27.3 UAE mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  105. 7.28 Turkey
  106. 7.28.1 Turkey mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  107. 7.28.2 Turkey mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  108. 7.28.3 Turkey mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  109. 7.29 Iran
  110. 7.29.1 Iran mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  111. 7.29.2 Iran mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  112. 7.29.3 Iran mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
  113. 7.30 Egypt
  114. 7.30.1 Egypt mRNA Vaccine Drugs Development Services Sales Value Growth Rate (2021-2032)
  115. 7.30.2 Egypt mRNA Vaccine Drugs Development Services Sales Value Share by Type, 2025 VS 2032
  116. 7.30.3 Egypt mRNA Vaccine Drugs Development Services Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 ReciBioPharm
  2. 8.1.1 ReciBioPharm Company Information
  3. 8.1.2 ReciBioPharm Business Overview
  4. 8.1.3 ReciBioPharm mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
  5. 8.1.4 ReciBioPharm mRNA Vaccine Drugs Development Services Product Portfolio
  6. 8.1.5 ReciBioPharm Recent Developments
  7. 8.2 Merck
  8. 8.2.1 Merck Company Information
  9. 8.2.2 Merck Business Overview
  10. 8.2.3 Merck mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Merck mRNA Vaccine Drugs Development Services Product Portfolio
  12. 8.2.5 Merck Recent Developments
  13. 8.3 Samsung Biologics
  14. 8.3.1 Samsung Biologics Company Information
  15. 8.3.2 Samsung Biologics Business Overview
  16. 8.3.3 Samsung Biologics mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Samsung Biologics mRNA Vaccine Drugs Development Services Product Portfolio
  18. 8.3.5 Samsung Biologics Recent Developments
  19. 8.4 Thermo Fisher Scientific
  20. 8.4.1 Thermo Fisher Scientific Company Information
  21. 8.4.2 Thermo Fisher Scientific Business Overview
  22. 8.4.3 Thermo Fisher Scientific mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
  23. 8.4.4 Thermo Fisher Scientific mRNA Vaccine Drugs Development Services Product Portfolio
  24. 8.4.5 Thermo Fisher Scientific Recent Developments
  25. 8.5 Lonza
  26. 8.5.1 Lonza Company Information
  27. 8.5.2 Lonza Business Overview
  28. 8.5.3 Lonza mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Lonza mRNA Vaccine Drugs Development Services Product Portfolio
  30. 8.5.5 Lonza Recent Developments
  31. 8.6 Ricoh Group
  32. 8.6.1 Ricoh Group Company Information
  33. 8.6.2 Ricoh Group Business Overview
  34. 8.6.3 Ricoh Group mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Ricoh Group mRNA Vaccine Drugs Development Services Product Portfolio
  36. 8.6.5 Ricoh Group Recent Developments
  37. 8.7 Aldevron
  38. 8.7.1 Aldevron Company Information
  39. 8.7.2 Aldevron Business Overview
  40. 8.7.3 Aldevron mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Aldevron mRNA Vaccine Drugs Development Services Product Portfolio
  42. 8.7.5 Aldevron Recent Developments
  43. 8.8 Wuxi Biologics
  44. 8.8.1 Wuxi Biologics Company Information
  45. 8.8.2 Wuxi Biologics Business Overview
  46. 8.8.3 Wuxi Biologics mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Wuxi Biologics mRNA Vaccine Drugs Development Services Product Portfolio
  48. 8.8.5 Wuxi Biologics Recent Developments
  49. 8.9 Genscript Probio
  50. 8.9.1 Genscript Probio Company Information
  51. 8.9.2 Genscript Probio Business Overview
  52. 8.9.3 Genscript Probio mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Genscript Probio mRNA Vaccine Drugs Development Services Product Portfolio
  54. 8.9.5 Genscript Probio Recent Developments
  55. 8.10 Novoprotein
  56. 8.10.1 Novoprotein Company Information
  57. 8.10.2 Novoprotein Business Overview
  58. 8.10.3 Novoprotein mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
  59. 8.10.4 Novoprotein mRNA Vaccine Drugs Development Services Product Portfolio
  60. 8.10.5 Novoprotein Recent Developments
  61. 8.11 Porton Advanced Solutions
  62. 8.11.1 Porton Advanced Solutions Company Information
  63. 8.11.2 Porton Advanced Solutions Business Overview
  64. 8.11.3 Porton Advanced Solutions mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
  65. 8.11.4 Porton Advanced Solutions mRNA Vaccine Drugs Development Services Product Portfolio
  66. 8.11.5 Porton Advanced Solutions Recent Developments
  67. 8.12 Precision NanoSystems
  68. 8.12.1 Precision NanoSystems Company Information
  69. 8.12.2 Precision NanoSystems Business Overview
  70. 8.12.3 Precision NanoSystems mRNA Vaccine Drugs Development Services Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Precision NanoSystems mRNA Vaccine Drugs Development Services Product Portfolio
  72. 8.12.5 Precision NanoSystems Recent Developments
9 Concluding Insights
    10 Appendix
    1. 10.1 Reasons for Doing This Study
    2. 10.2 Research Methodology
    3. 10.3 Research Process
    4. 10.4 Authors List of This Report
    5. 10.5 Data Source
    6. 10.5.1 Secondary Sources
    7. 10.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst